Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor... Guideline Summary Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary Julie R. Brahmer, Christina Lacchetti, and John A. Thompson Johns Hopkins Kimmel Cancer Center, Immune checkpoint inhibitors (ICPi) have Nivolumab is also approved for use in Baltimore, MD; American Society of Clinical revolutionized the treatment of many types hepatocellular carcinoma and patients Oncology, Alexandria, VA; University of of cancers. ICPis work by blocking path- with renal cell carcinoma. In addition, the Washington; and Fred Hutchinson Cancer Research Center, Seattle, WA ways, called checkpoints, and these check- combination of ipilimumab and nivolu- point pathways are mechanisms for the mab for patients with advanced mela- human immune system to control the im- noma has received US Food and Drug mune response. The immune checkpoint Administration approval. Most recently, proteins, cytotoxic T lymphocyte–associated the programmed death ligand-1 anti- 4(CTLA-4)andprogrammeddeath1(PD-1), bodies, atezolizumab (approved for use are receptors that are expressed on the in urothelial cancers and non–small-cell surface of cytotoxic T cells that interact with lung cancer), durvalumab (approved for their ligands—CD80/CD86 in the case of use in urothelial cancers), and avelumab CTLA-4, and programmed death ligand-1 (approved for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Oncology Practice Wolters Kluwer Health

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary

Loading next page...
 
/lp/wolters-kluwer-health/management-of-immune-related-adverse-events-in-patients-treated-with-cbvAlAQIh2

References (4)

Publisher
Wolters Kluwer Health
Copyright
Copyright (C) 2018 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1554-7477
DOI
10.1200/JOP.18.00005
Publisher site
See Article on Publisher Site

Abstract

Guideline Summary Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary Julie R. Brahmer, Christina Lacchetti, and John A. Thompson Johns Hopkins Kimmel Cancer Center, Immune checkpoint inhibitors (ICPi) have Nivolumab is also approved for use in Baltimore, MD; American Society of Clinical revolutionized the treatment of many types hepatocellular carcinoma and patients Oncology, Alexandria, VA; University of of cancers. ICPis work by blocking path- with renal cell carcinoma. In addition, the Washington; and Fred Hutchinson Cancer Research Center, Seattle, WA ways, called checkpoints, and these check- combination of ipilimumab and nivolu- point pathways are mechanisms for the mab for patients with advanced mela- human immune system to control the im- noma has received US Food and Drug mune response. The immune checkpoint Administration approval. Most recently, proteins, cytotoxic T lymphocyte–associated the programmed death ligand-1 anti- 4(CTLA-4)andprogrammeddeath1(PD-1), bodies, atezolizumab (approved for use are receptors that are expressed on the in urothelial cancers and non–small-cell surface of cytotoxic T cells that interact with lung cancer), durvalumab (approved for their ligands—CD80/CD86 in the case of use in urothelial cancers), and avelumab CTLA-4, and programmed death ligand-1 (approved for

Journal

Journal of Oncology PracticeWolters Kluwer Health

Published: Apr 1, 2018

There are no references for this article.